ArticleJournal of immunology (Baltimore, Md. : 1950)2008
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Action mechanism and cardiovascular effect of anthocyanins: a systematic review of animal and human studies.Journal of translational medicine · 2016Pooled it
- Redefining CRP in tissue injury and repair: more than an acute pro-inflammatory mediator.Frontiers in immunology · 2025Review
- [Relationship between lipid metabolism molecules in plasma and carotid atheroscle-rotic plaques, traditional cardiovascular risk factors, and dietary factors].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.Reviews in cardiovascular medicine · 2023Review
- C-Reactive Protein: Friend or Foe? Phylogeny From Heavy Metals to Modified Lipoproteins and SARS-CoV-2.Frontiers in cardiovascular medicine · 2022Review
- Conformationally Altered C-Reactive Protein Capable of Binding to Atherogenic Lipoproteins Reduces Atherosclerosis.Frontiers in immunology · 2020Article
- Functionality of C-Reactive Protein for Atheroprotection.Frontiers in immunology · 2019Review
- Evolution of C-Reactive Protein.Frontiers in immunology · 2019Review
- C-Reactive Protein in Atherothrombosis and Angiogenesis.Frontiers in immunology · 2018Review
- Functional Transformation of C-reactive Protein by Hydrogen Peroxide.The Journal of biological chemistry · 2017Article
- C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells.British journal of pharmacology · 2014Article
- Recognition functions of pentameric C-reactive protein in cardiovascular disease.Mediators of inflammation · 2014Review
- The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine.Journal of inflammation (London, England) · 2012Article
- Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis.The Journal of biological chemistry · 2012Article
- Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery.Mediators of inflammation · 2012Review
- Atherosclerosis-related functions of C-reactive protein.Cardiovascular & hematological disorders drug targets · 2010Article
- Identification of acidic pH-dependent ligands of pentameric C-reactive protein.The Journal of biological chemistry · 2010Article
- Study of the interaction of the C-reactive protein monomer with the U937 monocyte.Cellular & molecular biology letters · 2010Article
- The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolamine-generated acidic pH.Clinica chimica acta; international journal of clinical chemistry · 2009Article
- Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine.Clinica chimica acta; international journal of clinical chemistry · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The formation of low-density lipoprotein (LDL) cholesterol-loaded macrophage foam cells contributes to the development of atherosclerosis. C-reactive protein (CRP) binds to atherogenic forms of LDL, but the role of CRP in foam cell formation is unclear. In this study, we first explored the binding site on CRP for enzymatically modified LDL (E-LDL), a model of atherogenic LDL to which CRP binds. As reported previously, phosphocholine (PCh) inhibited CRP-E-LDL interaction, indicating the involvement of the PCh-binding site of CRP in binding to E-LDL. However, the amino acids Phe66 and Glu81 in CRP that participate in CRP-PCh interaction were not required for CRP-E-LDL interaction. Surprisingly, blocking of the PCh-binding site with phosphoethanolamine (PEt) dramatically increased the binding of CRP to E-LDL. The PEt-mediated enhancement in the binding of CRP to E-LDL was selective for E-LDL because PEt inhibited the binding of CRP to another PCh-binding site-ligand pneumococcal C-polysaccharide. Next, we investigated foam cell formation by CRP-bound E-LDL. We found that, unlike free E-LDL, CRP-bound E-LDL was inactive because it did not transform macrophages into foam cells. The function of CRP in eliminating the activity of E-LDL to form foam cells was not impaired by the presence of PEt. Combined data lead us to two conclusions. First, PEt is a useful compound because it potentiates the binding of CRP to E-LDL and, therefore, increases the efficiency of CRP to prevent transformation of macrophages into E-LDL-loaded foam cells. Second, the function of CRP to prevent formation of foam cells may influence the process of atherogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.